Subha Basu

Bio:

Subha focuses on assessing the scientific, clinical and commercial potential of therapeutics, known as asset strategy. Leading his own consulting firm, Converge Advisory Group, and previously at leading clinical and commercial services organizations, he assists clients with Corporate Strategy, New Product Development, Launch Planning, BD&L / M&A and Clinical Operations. He has also worked in-house at Pfizer, Lilly, Takeda and Boehringer Ingelheim. His previous experience include IQVIA, Becton Dickinson and Frost & Sullivan.

Subha holds a bachelor's degree from Berkeley, a PhD from SUNY - Downstate, a Post-Doctoral Fellowship from Stanford and an MBA from Carnegie Mellon. He also holds joint faculty appointments at New York University and SUNY - Old Westbury, teaching his self-developed class of Pharma Asset Strategy (PAS), as well as Immunology and Microbiology. Additionally, he trains current and future biopharma professionals online through PrimerProf, Primers for Professionals.